These data support the main findings described in 'The STELLAR trial: A phase II/III study of high-dose, intermittent sunitinib in patients with recurrent glioblastoma.
The data contains the results from the STELLAR trial, registered on ClinicalTrials.gov (NCT03025893). In total 55 patients were randomized 1:1 between treatment with high-dose intermittent sunitinib (either 300mg Q1W or 700mg Q2W) and lomustine. The trial was performed in three centers in the Netherlands (AmsterdamUMC, UMCG and Radboudumc).